Pharma – Evogene

AI-First
Innovation

Evogene is an AI-first company transforming drug discovery through its proprietary ChemPass AI platform, encompassing virtual screening and de novo multi-property molecule design capabilities.

Multi-Disciplinary
Expertise

By integrating cutting-edge AI, computational chemistry, and life sciences expertise, we accelerate the creation of novel small molecules.

Proven Collaboration
Model

With a proven track record of successful collaborations, we partner with drug developers to drive access to breakthrough therapies.

OUR VISION

Pioneer groundbreaking novel therapies based on small molecules to improve global health

OUR MISSION

We merge life-science expertise with big data and cutting edge AI to efficiently discover and optimise breakthrough therapies

Harnessing Our Computational Legacy:
Driving Evogene’s Drug Discovery Unit

Evogene’s Drug Discovery Unit is at the forefront of innovation in small-molecule drug development, leveraging the company’s accumulated computational biology and chemistry expertise, built over 20 years.

Evogene has demonstrated the application of advanced artificial intelligence capabilities to accelerate the discovery and development of novel products across various life sciences sectors. These range from agriculture to the food industry and now extend into the pharmaceutical sector. These achievements are validated through successful collaborations between Evogene and its subsidiaries with and major industry players.

The primary mission of Evogene’s Drug Discovery Unit is to discover and optimize small molecules as leading candidates for drug development using Evogene’s proprietary ChemPass-AI platform, which represents cutting-edge technologies in computational chemistry.

Our Team

Dr. Hamutal Engel

Head of Product

Dr. Boaz Musafia

Product Manager

Dr. Roberto Olender

Head of Algorithms

Dr. Gabi Tarcic

VP Product

Technology

ChemPass-AI, Evogene’s Proprietary Platform

Drug discovery

Target Identification

Drug discovery

Hit Screening Powered by: DeepDock

Utilizing Deep learning to enhance rapid screening in large databases

DeepDock for improved hit rate

DeepDock enables ultra-fast computational screening of a 40-billion compound curated database using our proprietary in-house developed deep learning algorithms. This allows us to:

Efficiently screen a vast chemical space
Identify high-potential hits
Assess and prioritize purchasable molecules for immediate experimental testing

Drug discovery

Hit-to-Lead Powered by: ActiveSearch

Upgraded analogue search with propriety algorithem

Active Search for Novel Chemistry

ActiveSearch employs advanced analogue search algorithms that leverage experimentally validated molecules to systematically expand discovery within relevant chemical space:

Identifies structurally related analogues of validated molecules to improve hit rates
Prioritizes the most promising scaffolds for further exploration
Tailored ML QSAR models to predict molecule activity against a target

Drug discovery

Lead Optimization Powered by: ChempassGPT

De-novo design with in-house foundation model

ChemPass-GPT: AI-Powered Molecular Design (De-Novo Drug Creation with AI Guidance)

ChemPass-GPT applies generative AI principles to design completely new molecules that meet complex drug discovery requirements:

Generates drug-like molecules that satisfy multi-objective constraints
Proprietary AI GPT model: Trained on SMILES to generate NCEs with desired properties
Constraints-Based Generation: molecules that adhere to all specific desired properties
Unique IP: De-novo design leads to the creation of unique intellectual property

Preclinical Development

Clinical Studies

Pioneering a First-in-Class Technology

Drag to explore

Evogene Platform

The Vast Untapped Potential of Drug Discovery

The chemical space of potential drug-like molecules is incredibly vast, estimated to be between 10^20 and 10^60. To put that into perspective, it’s believed that we’ve explored less than 0.1% of this vast chemical universe.
This staggering number highlights how much of this space remains uncharted and underscores the urgent need for more effective discovery methods.

Limitations of Traditional AI-Drug Discovery

Current AI approaches in drug discovery often face limitations due to:

Small and Imbalanced Datasets: Leading to biased models and limited predictive power.

Redundant and Invalid Molecules: Generating molecules that are not novel or lack drug-like properties.

Lack of Uniqueness: Producing molecules that are too similar to existing compounds, hindering true innovation.

We are Unlocking the Uncharted: Expanding Chemical Space for Breakthrough Drug Discovery

Multi-Parameter Design Capabilities: Allows optimization for multiple drug-relevant parameters (e.g., potency, ADMET) from the start.

Trained on Diverse Datasets: Overcomes small and imbalanced dataset limitations by incorporating broad, chemically diverse data curated in-house.

Novelty-Driven Generation: Explicitly optimized to generate unique, drug-like molecules—avoiding redundancy and invalid candidates.

Full In-House Control: Enables rapid iteration, customization, and integration across pipelines, without dependency on third-party models.

Built for Scalability: Architecture supports ongoing expansion with new data, targets, and properties, ensuring continuous performance improvement.

New Frontiers in AI-Driven Drug Discovery

Merging the power of science and AI to explore novel molecular spaces

Partner with Us

AI-First Innovation

Multi-Disciplinary Expertise

Proven Collaboration Model

OUR VISION

OUR MISSION

Harnessing Our Computational Legacy: Driving Evogene’s Drug Discovery Unit

Our Team

Why Us

Unlocking the Untapped Potential of Chemical Space

Technology Differentiation

Vast Screening Capability

De-Novo Application

Multi-Constraint Optimization

First-in Class Foundation Model

Unique Capabilities

Multi disciplinary Expertise

AI-First Approach

Collaborative Partnership

Technology

ChemPass-AI, Evogene’s Proprietary Platform

Target Identification

Hit Screening Powered by: DeepDock

Hit-to-Lead Powered by: ActiveSearch

Lead Optimization Powered by: ChempassGPT

Preclinical Development

Clinical Studies

Pioneering a First-in-Class Technology

The Vast Untapped Potential of Drug Discovery

Limitations of Traditional AI-Drug Discovery

We are Unlocking the Uncharted: Expanding Chemical Space for Breakthrough Drug Discovery

Collaborations

Working Together: Our Collaborative Approach

Hit ID Screening

Lead Optimization

Target ID/ Preprocessing

Hit-to-Lead

Further Lead Development

Optimized Collaboration

Insight-Driven Partnerships

Accelerating Progress

Customizable Collaboration

Partnering Across the Globe

Latest News

Evogene Announces Collaboration with Google Cloud to Pioneer Generative AI Foundation Model for Novel Small Molecule Design

Dr. Ruth Gross, Evogene’s VP of Business Development for Pharma, to attend BIO International Convention 2024

Dr. Ruth Gross, Evogene’s VP of Business Development for Pharma, to attend HLTH 2024 in Las Vegas

Dr. Ruth Gross, Evogene’s VP of Business Development for Pharma, to attend BIO-Europe 2024

AI-First
Innovation

Multi-Disciplinary
Expertise

Proven Collaboration
Model

Harnessing Our Computational Legacy:
Driving Evogene’s Drug Discovery Unit

Multi disciplinary
Expertise

AI-First
Approach

Collaborative
Partnership